1. Risk Factors and Outcome of Chronic Graft-versus-Host Disease after Allogeneic Stem Cell Transplantation—Results from a Single-Center Observational Study 
Matthias Grube, Ernst Holler, Daniela Weber, Barbara Holler, Wolfgang Herr, Daniel Wolff 
Biology of Blood and Marrow Transplantation 
Volume 22, Issue 10, Pages (October 2016)
DOI: /j.bbmt
Copyright © 2016 The American Society for Blood and Marrow Transplantation Terms and Conditions

2. Figure 1 Maximum severity of cGVHD according to organ manifestation.
Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt )
Copyright © 2016 The American Society for Blood and Marrow Transplantation Terms and Conditions

3. Figure 2
(A) Cumulative incidence of TRM in relation to the presence of cGVHD. Cumulative incidence of TRM between patients without (n = 147) and with (n = 243) cGVHD was calculated by the Kaplan-Meier method. (B) Cumulative incidence of TRM in relation to the onset type of cGVHD. Cumulative incidence of TRM between patients with de novo (n = 76), quiescent (n = 156), and progressive (n = 11) onset of cGVHD was calculated by the Kaplan-Meier method. (C) Cumulative incidence of TRM in relation to the platelet count at the time of cGVHD onset. Cumulative incidence of TRM between patients with platelets of more than 100/nL (n = 165) and less (n = 78) than 100/nL at the time of GVHD onset was calculated by the Kaplan-Meier method. (D) Cumulative incidence of TRM in relation to grade of severity of cGVHD. Cumulative incidence of TRM between patients without (n = 147) and with mild (n = 62), moderate (n = 85), or severe (n = 96) cGVHD was calculated by the Kaplan-Meier method. (E) Cumulative incidence of TRM in relation to organ involvement of severe cGVHD. Cumulative incidence of TRM between patients without cGVHD (n = 147) and patients with severe cGVHD with (n = 59) or without (n = 37) lung, liver, or gastrointestinal (GI) tract involvement (lung/liver/GI) was calculated by the Kaplan-Meier method.
Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt )
Copyright © 2016 The American Society for Blood and Marrow Transplantation Terms and Conditions

4. Figure 3
(A) Cumulative incidence of relapse in relation to the grade of cGVHD. Cumulative incidence of relapse between patients without (n = 147) and with mild (n = 62), moderate (n = 85), or severe (n = 96) cGVHD was calculated by the Kaplan-Meier method. (B) Cumulative incidence of relapse in relation to organ involvement of severe cGVHD. Cumulative incidence of relapse between patients without cGVHD (n = 147) and patients with severe cGVHD with (n = 59) or without (n = 37) lung, liver, or gastrointestinal (GI) tract involvement was calculated by the Kaplan-Meier method.
Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt )
Copyright © 2016 The American Society for Blood and Marrow Transplantation Terms and Conditions

5. Figure 4
(A) Overall survival in relation to the onset type of cGVHD. Overall survival between patients with de novo (n = 76), quiescent (n = 156), and progressive (n = 11) onset of cGVHD was calculated by the Kaplan-Meier method. (B) Overall survival in relation to the platelet count at the time of cGVHD onset. Overall survival between patients with platelets of more than 100/nL (n = 165) and less (n = 78) than 100/nL at the time of GVHD onset was calculated by the Kaplan-Meier method. (C) Overall survival in relation to the grade of cGVHD. Overall survival between patients without (n = 147) and with mild (n = 62), moderate (n = 85), or severe (n = 96) cGVHD was calculated by the Kaplan-Meier method. (D) Overall survival in relation to organ involvement of severe cGVHD. Overall survival between patients without cGVHD (n = 147) and patients with severe cGVHD with (n = 59) or without (n = 37) lung, liver, or gastrointestinal (GI) tract involvement was calculated by the Kaplan-Meier method.
Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt )
Copyright © 2016 The American Society for Blood and Marrow Transplantation Terms and Conditions